Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LATE-R Trial: Axicabtagene Ciloleucel in Late Relapse DLBCL
NCT07254754Phase 2Recruiting
- Sponsor
- GELTAMO
- Start
- Nov 2024
- Primary completion
- Jan 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of axicabtagene ciloleucel in diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), follicular lymphoma (FL), sponsored by GELTAMO. Started Nov 2024; status: recruiting.
02
Drugs
axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT07254754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07254754.